These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30925535)

  • 21. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
    Sadanand S; Suscovich TJ; Alter G
    Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progress in HIV vaccine development.
    Hsu DC; O'Connell RJ
    Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvants: tailoring humoral immune responses.
    McElrath MJ
    Curr Opin HIV AIDS; 2017 May; 12(3):278-284. PubMed ID: 28257301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo protection by broadly neutralizing HIV antibodies.
    van Gils MJ; Sanders RW
    Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in HIV-1 Vaccine Development.
    Gao Y; McKay PF; Mann JFS
    Viruses; 2018 Apr; 10(4):. PubMed ID: 29614779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
    Wieczorek L; Krebs SJ; Kalyanaraman V; Whitney S; Tovanabutra S; Moscoso CG; Sanders-Buell E; Williams C; Slike B; Molnar S; Dussupt V; Alam SM; Chenine AL; Tong T; Hill EL; Liao HX; Hoelscher M; Maboko L; Zolla-Pazner S; Haynes BF; Pensiero M; McCutchan F; Malek-Salehi S; Cheng RH; Robb ML; VanCott T; Michael NL; Marovich MA; Alving CR; Matyas GR; Rao M; Polonis VR
    J Virol; 2015 Aug; 89(15):7478-93. PubMed ID: 25972551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV Immunology Goes Out On a Limb.
    Doria-Rose NA; Mascola JR
    Immunity; 2016 May; 44(5):1088-90. PubMed ID: 27192575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
    van Gils MJ; Sanders RW
    Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV Vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity.
    Wren L; Kent SJ
    Hum Vaccin; 2011 Apr; 7(4):466-73. PubMed ID: 21389779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
    Subbaraman H; Schanz M; Trkola A
    Retrovirology; 2018 Jul; 15(1):52. PubMed ID: 30055627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The antibody response in HIV-1-infected donors.
    Richardson SI; Moore PL
    Curr Opin HIV AIDS; 2019 Jul; 14(4):233-239. PubMed ID: 31033730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem.
    Koff WC
    Vaccine; 2012 Jun; 30(29):4310-5. PubMed ID: 22100891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models.
    Pollara J; Jones DI; Huffman T; Edwards RW; Dennis M; Li SH; Jha S; Goodman D; Kumar A; LaBranche CC; Montefiori DC; Fouda GG; Hope TJ; Tomaras GD; Staats HF; Ferrari G; Permar SR
    J Virol; 2019 May; 93(10):. PubMed ID: 30842326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV vaccine development--improving on natural immunity.
    Johnston MI; Fauci AS
    N Engl J Med; 2011 Sep; 365(10):873-5. PubMed ID: 21899447
    [No Abstract]   [Full Text] [Related]  

  • 36. Translational research insights from completed HIV vaccine efficacy trials.
    Tieu HV; Rolland M; Hammer SM; Sobieszczyk ME
    J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2():S150-4. PubMed ID: 23764628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV/AIDS Vaccines: 2018.
    Robinson HL
    Clin Pharmacol Ther; 2018 Dec; 104(6):1062-1073. PubMed ID: 30099743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is developing an HIV-1 vaccine possible?
    Haynes BF; Liao HX; Tomaras GD
    Curr Opin HIV AIDS; 2010 Sep; 5(5):362-7. PubMed ID: 20978375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Neutralizing Antibody Response to the HIV-1 Env Protein.
    Moore PL
    Curr HIV Res; 2018; 16(1):21-28. PubMed ID: 29173180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.